BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32566010)

  • 1. Downregulation of ST3GAL5 is associated with muscle invasion, high grade and a poor prognosis in patients with bladder cancer.
    Ouyang S; Liu JH; Ni Z; Ding GF; Wang QZ
    Oncol Lett; 2020 Jul; 20(1):828-840. PubMed ID: 32566010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of CLIC3 mRNA overexpression in bladder cancer.
    Chen M; Zhang S; Wen X; Cao H; Gao Y
    PeerJ; 2020; 8():e8348. PubMed ID: 31934512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative bioinformatics analysis of prognostic and differentially expressed genes in non-muscle and muscle invasive bladder cancer.
    Silva TA; Azevedo H
    J Proteomics; 2020 Oct; 229():103951. PubMed ID: 32860965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioinformatic Identification of Potential Hub Genes in Muscle-Invasive Bladder Urothelial Carcinoma.
    Guo C; Shao T; Wei D; Li C; Liu F; Li M; Gao Z; Bao G
    Cell Transplant; 2020; 29():963689720965178. PubMed ID: 33035117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer.
    Shim UJ; Lee IS; Kang HW; Kim J; Kim WT; Kim IY; Ryu KH; Choi YH; Moon SK; Kim YJ; Yun SJ; Lee SC; Kim WJ
    Korean J Urol; 2013 Sep; 54(9):631-7. PubMed ID: 24044099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of ST3GAL5 as a prognostic biomarker correlating with CD8
    Liu J; Li M; Wu J; Qi Q; Li Y; Wang S; Liang S; Zhang Y; Zhu Z; Huang R; Yan J; Zhu R
    Front Immunol; 2022; 13():979605. PubMed ID: 36172374
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Kim K; Byun YJ; Zheng CM; Moon S; Jo SJ; Kang HW; Kim WT; Choi YH; Moon SK; Kim WJ; Piao XM; Yun SJ
    Investig Clin Urol; 2024 Jan; 65(1):94-103. PubMed ID: 38197756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the tumor microenvironment in bladder cancer and exploring the prognostic genes by single-cell RNA sequencing.
    Chen Z; Chen D; Song Z; Lv Y; Qi D
    Front Oncol; 2022; 12():1105026. PubMed ID: 36741702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel tumor suppressing gene,
    Piao XM; Jeong P; Yan C; Kim YH; Byun YJ; Xu Y; Kang HW; Seo SP; Kim WT; Lee JY; Kim IY; Moon SK; Choi YH; Cha EJ; Yun SJ; Kim WJ
    Oncol Lett; 2020 Jan; 19(1):476-486. PubMed ID: 31897161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer.
    Fang Z; Dai W; Wang X; Chen W; Shen C; Ye G; Li L
    Tumour Biol; 2016 Jun; 37(6):8075-82. PubMed ID: 26715266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the Expression and Prognostic Value of Annexin Family Proteins in Bladder Cancer.
    Wu W; Jia G; Chen L; Liu H; Xia S
    Front Genet; 2021; 12():731625. PubMed ID: 34484309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.
    Martínez-Fernández M; Dueñas M; Feber A; Segovia C; García-Escudero R; Rubio C; López-Calderón FF; Díaz-García C; Villacampa F; Duarte J; Gómez-Rodriguez MJ; Castellano D; Rodriguez-Peralto JL; de la Rosa F; Beck S; Paramio JM
    Oncotarget; 2015 Dec; 6(39):42258-75. PubMed ID: 26517683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.
    Cheng X; Liu X; Liu X; Guo Z; Sun H; Zhang M; Ji Z; Sun W
    Front Oncol; 2018; 8():494. PubMed ID: 30450336
    [No Abstract]   [Full Text] [Related]  

  • 15. Expression and prognostic value of SULT1A2 in bladder cancer.
    Chao Y; Ou Q; Shang J
    Exp Ther Med; 2021 Jul; 22(1):779. PubMed ID: 34055078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of the ASPM gene is associated with aggressiveness and poor outcome in bladder cancer.
    Xu Z; Zhang Q; Luh F; Jin B; Liu X
    Oncol Lett; 2019 Feb; 17(2):1865-1876. PubMed ID: 30675249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Core Genes and Key Pathways via Integrated Analysis of Gene Expression and DNA Methylation Profiles in Bladder Cancer.
    Zhang Y; Fang L; Zang Y; Xu Z
    Med Sci Monit; 2018 May; 24():3024-3033. PubMed ID: 29739919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry.
    Wu M; Sun Q; Mo CH; Pang JS; Hou JY; Pang LL; Lu HP; Dang YW; Fang SJ; Tang D; Chen G; Feng ZB
    Oncol Rep; 2019 Jul; 42(1):151-175. PubMed ID: 31059074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of RAC3 in bladder cancer predicts adverse clinical outcome and increased tumor immune response.
    Ou-Yang S; Liu JH; Wang QZ
    Int J Clin Exp Pathol; 2020; 13(12):2937-2949. PubMed ID: 33425095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4.
    Bellmunt J
    Biomedicines; 2018 Aug; 6(3):. PubMed ID: 30072631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.